AZD3355 Dose-escalation Study in Healthy Males

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00757419
Recruitment Status : Completed
First Posted : September 23, 2008
Last Update Posted : December 7, 2010
Information provided by:

September 22, 2008
September 23, 2008
December 7, 2010
September 2008
December 2008   (Final data collection date for primary outcome measure)
Safety variables (Adverse event reporting, ECG, blood pressure, pulse rate, urine weight and osmolality, body temperature, blood and urine laboratory values) [ Time Frame: During the study ]
Same as current
Complete list of historical versions of study NCT00757419 on Archive Site
Pharmacokinetic variables [ Time Frame: Several occasions during the study days ]
Same as current
Not Provided
Not Provided
AZD3355 Dose-escalation Study in Healthy Males
A Phase 1 Single Centre Single-blind Randomised Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD3355 After Administration of Single Ascending Doses and Multiple Repeated Doses in Healthy Male Volunteers
The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inactive substance"). Safety and tolerability variables will be closely monitored throughout the study.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Reflux Disease
  • Drug: AZD3355
    capsules, oral, single or twice daily dose
    Other Name: Lesogaberan
  • Drug: Placebo
    To match dosing of AZD3355
  • Experimental: 1
    Intervention: Drug: AZD3355
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects without concurrent diseases who do not require any medical treatments
  • Provision of signed informed consent.

Exclusion Criteria:

  • History of somatic disease/condition, which may interfere with the objectives for the study, as judged by the investigator.
  • Clinically significant illness or clinically relevant trauma within the 2 weeks prior to the administration of the investigational product, as judged by the investigator.
  • History of clinically significant orthostatic reaction or syncope
  • Clinically important abnormalities related to the heart function
Sexes Eligible for Study: Male
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
EudraCTnr: 2008-003578-16
Not Provided
Not Provided
Debra G. Silberg, MD, PhD, Medical Science Director, AZD3355, AstraZeneca Pharmaceuticals
Not Provided
Principal Investigator: Marianne Hartford CPU Avd 102, Gröna Stråket 12, Sahlgrenska Universitetssjukhuset, 413 45 Göteborg
Study Director: Eva Ersdal AstraZeneca R&D, Mölndal, Sweden
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP